Last reviewed · How we verify

Hornel (FALECALCITRIOL)

Taisho Pharmaceutical · FDA-approved active Small molecule ✓ Verified May 2026 Quality 16/100

Hornel (generic name: FALECALCITRIOL) is a Small molecule drug developed by Taisho Pharmaceutical. It is currently FDA-approved for Hypoparathyroidism, Osteomalacia, Rickets.

Hornel is a small molecule with the synonyms FALECALCITRIOL, FALECALCITORIOL, and others.

At a glance

Generic nameFALECALCITRIOL
SponsorTaisho Pharmaceutical
ModalitySmall molecule
Therapeutic areaMetabolic
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Hornel

What is Hornel?

Hornel (FALECALCITRIOL) is a Small molecule drug developed by Taisho Pharmaceutical, indicated for Hypoparathyroidism, Osteomalacia, Rickets.

What is Hornel used for?

Hornel is indicated for Hypoparathyroidism, Osteomalacia, Rickets.

Who makes Hornel?

Hornel is developed and marketed by Taisho Pharmaceutical (see full Taisho Pharmaceutical pipeline at /company/taisho-pharmaceutical).

What is the generic name of Hornel?

FALECALCITRIOL is the generic (nonproprietary) name of Hornel.

What development phase is Hornel in?

Hornel is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing